Zydus Lifesciences has received an upgraded ESG rating of 68 from the independent agency ESG Risk Assessments and Insights Limited (ESGRAIL). This score reflects an improvement over the previous year’s rating of 66. The assessment was conducted independently by the agency based on publicly available data, without direct engagement from the company. The report was officially received by the company on April 9, 2026.
ESG Performance Highlights
Zydus Lifesciences has demonstrated a positive trajectory in its environmental, social, and governance practices. According to the latest assessment provided by ESGRAIL, the company achieved an overall score of 68. This represents a measured improvement from the score of 66 recorded during the previous year, highlighting the company’s ongoing commitment to sustainable business operations.
Independent Assessment Process
It is important to note that this rating was generated through an independent evaluation process. Zydus Lifesciences did not engage ESGRAIL to conduct this assessment. Instead, the rating agency compiled its report by exclusively analyzing publicly available information concerning the company’s activities and disclosures. The company received the final notification of this updated rating on April 9, 2026, confirming its continued transparency and focus on evolving ESG standards within the pharmaceutical industry.
Source: BSE
